Daily Stock Analysis, AGLE, Aeglea Bio Therapeutics Inc, priceseries

Aeglea Bio Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
9.95
Close
9.72
High
10.12
Low
9.33
Previous Close
9.89
Daily Price Gain
-0.17
YTD High
11.35
YTD High Date
Mar 20, 2018
YTD Low
4.95
YTD Low Date
Jan 8, 2018
YTD Price Change
4.34
YTD Gain
80.67%
52 Week High
11.35
52 Week High Date
Mar 20, 2018
52 Week Low
2.81
52 Week Low Date
Aug 17, 2017
52 Week Price Change
5.29
52 Week Gain
119.41%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 9. 2017
4.59
Mar 7. 2017
5.71
17 Trading Days
24.36%
Link
LONG
Aug 24. 2017
3.11
Sep 26. 2017
4.61
22 Trading Days
48.14%
Link
LONG
Jan 19. 2018
6.75
Jan 23. 2018
7.21
2 Trading Days
6.81%
Link
LONG
Feb 27. 2018
6.44
Mar 26. 2018
9.60
19 Trading Days
49.07%
Link
LONG
Apr 27. 2018
8.84
May 21. 2018
10.32
16 Trading Days
16.75%
Link
Company Information
Stock Symbol
AGLE
Exchange
NasdaqGM
Company URL
http://www.aegleabio.com
Company Phone
(512) 942-2935
CEO
David G. Lowe
Headquarters
Texas
Business Address
901 S. MOPAC EXPRESSWAY, STE. 250, BARTON OAKS PLAZA ONE, AUSTIN, TX 78746
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001636282
About

Aeglea Biotherapeutics, Inc. operates as a biopharmaceutical company, which engages in developing engineered human enzymes for the treatment of inborn errors of metabolism and cancer. It develops AEB1102, an amino acid for the degradation of arginine in the circulation, as well as for the treatment of hyperargininemia and cancer; and AEB3103, an engineered and PEGylated human cysteine/cystine degrading enzyme that increases oxidative stress through glutathione depletion for treatment of hematologic and solid malignancies; AEB2109, an engineered human enzyme that degrades methionine for the treatment of solid tumors; and AEB4104, an engineered human enzyme that degrades homocysteine in the circulation for the treatment of inborn error of metabolism homocystinuria. The company was founded in December 13, by by George Georgiou and David G. Lowe and is headquartered in Austin, TX.

Description

Aeglea Biotherapeutics, Inc., a biopharmaceutical company, engages in developing engineered human enzymes for the treatment of inborn errors of metabolism and cancer. It develops AERase/AEB1102, an amino acid for the degradation of arginine in the circulation, as well as for the treatment of hyperargininemia and cancer; and AECase/AEB3103, an engineered and PEGylated human cysteine/cystine degrading enzyme that increases oxidative stress through glutathione depletion for treatment of hematologic and solid malignancies. The company also engages in developing AEMase/AEB2109, an engineered human enzyme that degrades methionine for the treatment of solid tumors; and AEB4104, an engineered human enzyme that degrades homocysteine in the circulation for the treatment of inborn error of metabolism homocystinuria. It has a strategic partnership with KBI Biopharma. Aeglea Biotherapeutics, Inc. was formerly known as Aeglea BioTherapeutics Holdings, LLC. The company was founded in 2013 and is based in Austin, Texas.